Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Cizzle Biotechnology Holdings PLC ( (GB:CIZ) ).
Cizzle Biotechnology Holdings PLC has signed a Letter of Intent with a leading UK clinical diagnostic group to verify and validate its CIZ1B biomarker test in partnership with the NHS. This move is part of Cizzle’s strategy to expand its early lung cancer detection test across the UK and Europe, aligning with the NHS’s goals to improve early cancer diagnosis. The company has already secured a licensing agreement in North America and the Caribbean and is working on further partnerships to enhance its global market presence.
More about Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings PLC is a UK-based company specializing in the development of early cancer diagnostic tests. The company’s primary product is the CIZ1B biomarker test, a non-invasive blood test aimed at early-stage lung cancer detection. This test is based on pioneering research by Professor Dawn Coverley and her team at the University of York. Cizzle Biotechnology has entered commercial licensing agreements and collaborations to expand its market reach.
Average Trading Volume: 1,463,715
Technical Sentiment Signal: Hold
Current Market Cap: £6.74M
For an in-depth examination of CIZ stock, go to TipRanks’ Overview page.